Phase 1 Trial of Alrizomadlin Shows Promise in Targeting Metastatic Salivary Gland Cancers

May 12, 2026
Read time: <5 mins
Cancer

What happens when one of the rarest cancers has almost no treatment options left? University of Michigan researchers are testing a new targeted drug that is showing encouraging results against aggressive salivary gland cancers, offering fresh hope for patients facing a disease where therapies have remained largely unchanged for years.

Share:
We use cookies to ensure you get the best experience on our website. By using this site, you accept our use of cookies.